🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 3 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 20/01/2012 | 36,98 | 37,15 | 36,19 | 36,31 | -1,79% | 2,60% | 2.305.700 |
| 19/01/2012 | 37,50 | 37,89 | 36,82 | 36,97 | -1,33% | 2,85% | 2.983.600 |
| 18/01/2012 | 36,60 | 37,59 | 36,25 | 37,47 | +2,63% | 3,66% | 4.279.200 |
| 17/01/2012 | 36,72 | 37,30 | 36,25 | 36,51 | -0,81% | 2,86% | 2.180.400 |
| 13/01/2012 | 36,86 | 36,86 | 35,98 | 36,81 | -0,70% | 2,39% | 1.984.600 |
| 12/01/2012 | 37,30 | 37,47 | 36,00 | 37,07 | -0,67% | 3,94% | 2.813.900 |
| 11/01/2012 | 36,44 | 37,45 | 35,74 | 37,32 | +2,75% | 4,69% | 3.943.300 |
| 10/01/2012 | 35,97 | 36,54 | 35,50 | 36,32 | +1,79% | 2,89% | 3.251.700 |
| 09/01/2012 | 35,00 | 36,17 | 34,63 | 35,68 | +4,79% | 4,40% | 4.657.200 |
| 06/01/2012 | 33,21 | 34,54 | 33,14 | 34,05 | +2,81% | 4,22% | 3.436.800 |
| 05/01/2012 | 32,25 | 33,54 | 32,16 | 33,12 | +2,86% | 4,28% | 3.208.900 |
| 04/01/2012 | 32,22 | 32,59 | 32,04 | 32,20 | -0,09% | 1,71% | 2.660.300 |
| 03/01/2012 | 33,82 | 33,99 | 32,21 | 32,23 | -2,95% | 5,26% | 2.415.600 |
| 30/12/2011 | 32,71 | 33,40 | 32,45 | 33,21 | +1,37% | 2,90% | 1.328.700 |
| 29/12/2011 | 32,38 | 32,83 | 32,00 | 32,76 | +0,99% | 2,56% | 864.400 |
| 28/12/2011 | 33,29 | 33,32 | 32,10 | 32,44 | -2,44% | 3,66% | 873.100 |
| 27/12/2011 | 32,83 | 33,54 | 32,58 | 33,25 | +1,25% | 2,92% | 1.017.600 |
| 23/12/2011 | 33,05 | 33,43 | 32,55 | 32,84 | -0,55% | 2,66% | 971.600 |
| 22/12/2011 | 32,91 | 33,28 | 32,55 | 33,02 | +0,09% | 2,22% | 1.422.100 |
| 21/12/2011 | 33,33 | 33,57 | 32,62 | 32,99 | -1,23% | 2,85% | 2.691.600 |
| 20/12/2011 | 33,71 | 34,45 | 33,22 | 33,40 | +0,57% | 3,65% | 3.134.300 |
| 19/12/2011 | 34,97 | 34,97 | 32,94 | 33,21 | -2,06% | 5,80% | 3.770.300 |
| 16/12/2011 | 32,69 | 34,08 | 32,23 | 33,91 | +7,89% | 5,66% | 9.682.300 |
| 15/12/2011 | 30,84 | 32,46 | 30,32 | 31,43 | +2,91% | 6,94% | 5.973.600 |
| 14/12/2011 | 29,41 | 30,85 | 29,12 | 30,54 | +6,56% | 5,88% | 5.333.300 |
| 13/12/2011 | 29,57 | 29,62 | 28,49 | 28,66 | -2,35% | 3,82% | 2.223.700 |
| 12/12/2011 | 29,30 | 29,43 | 28,71 | 29,35 | -0,07% | 2,46% | 1.856.300 |
| 09/12/2011 | 29,80 | 29,82 | 29,02 | 29,37 | +2,84% | 2,68% | 2.250.500 |
| 08/12/2011 | 29,59 | 29,73 | 28,46 | 28,56 | -3,68% | 4,29% | 2.537.300 |
| 07/12/2011 | 29,57 | 29,91 | 28,94 | 29,65 | -0,03% | 3,28% | 3.391.400 |